Effectiveness of the Cytokine Hemadsorption on Sepsis

Completed

• Conditions: Interleukin-6

• Registration Number: NCT05057455
• Lead Sponsor: Biruni University

Brief Summary

In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Primary Completion: 2020-12-30
• Study Completion: 2021-02-15
• Status Verified: 2021-09
• Study First Submitted: 2021-09-16
• Study First Submitted QC: 2021-09-16
• Last Update Submitted: 2021-09-16
• Study First Posted: 2021-09-27
• Last Update Posted: 2021-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock
• detection of gram-negative bacterial agent in blood or sputum culture.
• patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis.

Exclusion Criteria

• had uncontrolled hemorrhage,
• diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4
• cancer at the end stage or admitted with acute coronary syndrome.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-6	1 YEARS	levels of IL-6

Trial Locations

Locations (1)

Ilke Kupeli; 🇹🇷 Istanbul, Turkey